Addition of a purine analogue (cladribine or fludarabine) to induction regimen in patients with acute myeloid leukaemia.

Trial Profile

Addition of a purine analogue (cladribine or fludarabine) to induction regimen in patients with acute myeloid leukaemia.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Apr 2012

At a glance

  • Drugs Cladribine (Primary) ; Fludarabine (Primary) ; Cytarabine; Daunorubicin
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Apr 2012 Results published in the Journal of Clinical Oncology.
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top